Treatment with leptin, the hormone associated with fullness or satiety, reverses hyperglycemia in animal models of poorly controlled type 1 (T1D) and type 2 (T2D) diabetes by suppressing the neuroendocrine pathways that cause blood glucose levels to soar, a Yale-led team of researchers has found. The study appears in Nature Medicine.